NINTTO: Nano-enabled IntraNasal delivery of Teriparatide for the Treatment of Osteoporosis

We plan to develop a nasal spray formulation of PTH1-34 for the treatment of osteoporosis using the CriticalSorb absorption enhancer. Osteoporosis is a prevalent disease (effecting 40% of women by age 80), characterised by reduced bone density and increased risk of fracture, particularly of the hip, wrist and spine, at a cost to the NHS of >£2bn per annum. PTH1-34 is the only drug available that stimulates the formation of new bone, but currently needs to be injected every day. Not only is this invasive method of drug administration not well liked by patients, but it is a complicated multi-step process and as osteoporosis patients are elderly they can find it difficult. The nasal spray we develop is expected to improve ease of use, increase patient compliance with the treatment regimen and increase efficacy with the aim of improving treatments and reducing healthcare costs.